AU2020223358A1 - Treating heart failure - Google Patents

Treating heart failure Download PDF

Info

Publication number
AU2020223358A1
AU2020223358A1 AU2020223358A AU2020223358A AU2020223358A1 AU 2020223358 A1 AU2020223358 A1 AU 2020223358A1 AU 2020223358 A AU2020223358 A AU 2020223358A AU 2020223358 A AU2020223358 A AU 2020223358A AU 2020223358 A1 AU2020223358 A1 AU 2020223358A1
Authority
AU
Australia
Prior art keywords
subject
mitochondria
composition
mitochondrial
pab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020223358A
Other languages
English (en)
Inventor
James D. MCCULLY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of AU2020223358A1 publication Critical patent/AU2020223358A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
AU2020223358A 2019-02-15 2020-02-14 Treating heart failure Pending AU2020223358A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806473P 2019-02-15 2019-02-15
US62/806,473 2019-02-15
PCT/US2020/018371 WO2020168247A1 (en) 2019-02-15 2020-02-14 Treating heart failure

Publications (1)

Publication Number Publication Date
AU2020223358A1 true AU2020223358A1 (en) 2021-09-09

Family

ID=72044848

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020223358A Pending AU2020223358A1 (en) 2019-02-15 2020-02-14 Treating heart failure

Country Status (7)

Country Link
US (1) US20220160782A1 (https=)
EP (1) EP3923963A4 (https=)
JP (2) JP7769545B2 (https=)
CN (1) CN113710255A (https=)
AU (1) AU2020223358A1 (https=)
CA (1) CA3130213A1 (https=)
WO (1) WO2020168247A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106536056B (zh) 2014-06-13 2021-07-16 儿童医学中心公司 分离线粒体的产品和方法
US11903974B2 (en) * 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
WO2017124037A1 (en) 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
WO2025184537A1 (en) * 2024-03-01 2025-09-04 The Board Of Trustees Of The Leland Stanford Junior University Bio-engineered mitochondria for targeted delivery to cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011757A1 (en) 2005-07-14 2007-01-25 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
IL183818A0 (en) 2007-06-10 2007-10-31 Shimon Harpaz Uniformly abrasive confectionery product and process therefor
US20090202606A1 (en) 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
WO2013171752A1 (en) * 2012-05-16 2013-11-21 Minovia Therapeutics Ltd. Compositions and methods for inducing angiogenesis
WO2015073396A1 (en) 2013-11-12 2015-05-21 The Brigham And Women's Hospital, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure
CN106536056B (zh) 2014-06-13 2021-07-16 儿童医学中心公司 分离线粒体的产品和方法
US11903974B2 (en) 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
WO2017124037A1 (en) * 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
JP7218897B2 (ja) 2016-11-16 2023-02-07 ルカ・サイエンス株式会社 心不全の治療及び／又は予防に用いるための心筋幹細胞の製造方法

Also Published As

Publication number Publication date
EP3923963A1 (en) 2021-12-22
EP3923963A4 (en) 2022-11-23
JP7769545B2 (ja) 2025-11-13
WO2020168247A1 (en) 2020-08-20
JP2026048627A (ja) 2026-03-17
JP2022519767A (ja) 2022-03-24
CA3130213A1 (en) 2020-08-20
CN113710255A (zh) 2021-11-26
US20220160782A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
AU2023201193B2 (en) Therapeutic use of mitochondria and combined mitochondrial agents
US20220160782A1 (en) Treating Heart Failure
Weixler et al. Autogenous mitochondria transplantation for treatment of right heart failure
McCully et al. Mitochondrial transplantation: the advance to therapeutic application and molecular modulation
Mao et al. Mesenchymal stem cells overexpressing integrin-linked kinase attenuate left ventricular remodeling and improve cardiac function after myocardial infarction
US20220347212A1 (en) Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents
WO2019028469A1 (en) FUNCTIONALIZED POLYMER MITOCHONDRIAL COMPOSITIONS AND METHODS OF USE IN CELL TRANSPLANTATION AND FOR MODIFYING METABOLIC PHENOTYPE
Kanemitsu et al. Insulin-like growth factor-1 enhances the efficacy of myoblast transplantation with its multiple functions in the chronic myocardial infarction rat model
RU2824501C2 (ru) Лечение сердечной недостаточности
Borenstein et al. Non-cultured cell transplantation in an ovine model of non-ischemic heart failure
HK40103035A (en) Therapeutic use of mitochondria and combined mitochondrial agents
HK40103035B (en) Therapeutic use of mitochondria and combined mitochondrial agents
HK40039519A (en) Therapeutic use of mitochondria and combined mitochondrial agents
CN111249448A (zh) Chir99021及fgf1的plga纳米颗粒在治疗缺血性心脏病药物中的应用
HK40000946A (en) Therapeutic use of mitochondria and combined mitochondrial agents
HK40000946B (en) Therapeutic use of mitochondria and combined mitochondrial agents